DOCSLIB.ORG

Pharmacogenetic Studies Investigating the Adverse Effects of Antipsychotics

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmacogenetic Studies Investigating the Adverse Effects of Antipsychotics online © ML Comm 0REVIEW ARTICLE0 Psychiatry Investig 2007;4:66-75 Print ISSN 1738-3684 / On-line ISSN 1976-3026 Pharmacogenetic Studies Investigating the Adverse Effects of Antipsychotics Heon-Jeong Lee, MD, PhD The pharmacogenetic study of antipsychotics has been developed along with the develop- Department of Psychiatry, ment of general techniques of genetic analysis. Because there are no significant differences Division of Brain Korea in the clinical efficacy of the various antipsychotics, it is important to prevent the adverse 21 for Biomedical Science, Korea University College of Medicine, effects of antipsychotics. Therefore, pharmacogenetic studies concerning antipsychotics have Seoul, Korea been primarily focused on their adverse effects. The most significant finding of the previous studies is the association between drug effects and drug metabolic polymorphisms, mainly in the cytochrome P450 (CYP) genes. Patients with genetically determined to be CYP poor metabolizers (PMs) may require lower doses of antipsychotic medications. On the other hand, CYP ultrarapid matabolizers (UMs) will need an increased dosage in order to obtain a therapeutic response. Genetic variations in the dopamine and serotonin receptor genes have been reported to be associated with the adverse effects of antipsychotics, reflecting the affinities that most antipsychotics have for these receptors. In particular, there is evidence to suggest an association between dopamine 2 receptor polymorphisms and a dopamine 3 receptor polymorphism and antipsychotic-induced tardive dyskinesia. Several studies were recently performed to determine the genetic susceptibility to antipsychotic-induced weight gain and metabolic syndrome. Adrenergic 2a receptor, leptin gene, and serotonin 2C receptor gene variants have been reported to be associated with drug-induced weight gain. Genetic tests before treatment will provide the necessary information on the patient’s metabolic status, which will aid in the appropriate adjustment of the therapeutic doses and the reduction of adverse reactions. Pharmacogenetic knowledge has obvious implications for the selection and improvement of antipsychotic treatment. These developments can be considered to be successes, but the objectives of bringing pharmacogenetic and pharmacogenomic research into psychiatric clinical practice are far from being realized. This review summarizes the findings of the previous research in the field. The current knowledge on the genetic predic- tion of drug metabolic status and drug-induced side effects will be reviewed and discussed. KEY WORDS: Pharmacogenetics, Antipsychotics, Adverse effects, Tardive dyskinesia, Weight gain. Psychiatry Investig 2007;4:66-75 Introduction Pharmacotherapy is a primary mode of treatment for the various psychiatric symp- toms of mental illnesses such as schizophrenia, bipolar disorder, major depression and organic mental disorders. The pharmacotherapy of psychiatric disorders is often Correspondence characterized by trial and error. Psychotropic drugs show a large variation in response Heon-Jeong Lee, MD, PhD Department of Psychiatry, and side effects. Genetic techniques seem to have a potential for use in the identifi- Korea University Anam Hospital, cation of biological predictors of drug response and side effects and may aid in the Korea University College of Medicine, establishment of tailored pharmacotherapy. The core hypothesis underlying pharma- 126-1 Anam-dong 5-ga, Seongbuk-gu, cogenetics is that genetic factors play a significant role in the differences between Seoul 136-705, Korea Tel +82-2-920-6721 individuals in response to medication and susceptibility to adverse effects. If these Fax +82-2-929-7679 genetic factors can be identified and understood, they may serve as predictors to E-mail [email protected] guide clinicians in tailoring medication to the individual patient. 66 www.psychiatryinvestigation.org ⓒ 2007 Official Journal of Korean Neuropsychiatric Association HJ Lee Antipsychotics are traditionally classified into two major casians.9 Some gene duplications (or multiplications) groups: first generation (or typical) antipsychotics (F- are responsible for the UM phenotype. The frequencies GAs), with strong affinities for the dopamine D2 recep- of CYP2D6 polymorphisms are subject to ethnic varia- tor (DRD2) among others, and the newer second gener- tion, with PMs representing 7-10% of Caucasians and ation (or atypical) antipsychotics (SGAs), with multiple only 1-2% of Asians.10 The metabolism of haloperidol receptor profiles.1,2 FGAs are usually associated with was severely reduced by PMs, and a reduced therapeutic acute extrapyramidal symptoms (EPS), such as Parkin- dose should be prescribed accordingly.11 It was recently sonism, acute dystonic reactions, akathisia and long- observed that CYP2D6 did not predict the response to lasting movement disorders such as tardive dyskinesia risperidone, but rather predicted the metabolic rate and (TD). The newer SGAs are characterized by a lower adverse effects of the drug.12-14 CYP1A2 is the main met- incidence of EPS. Adherence (compliance) to medication abolic pathway of clozapine and olanzapine.15,16 Among is an important factor in the management of schizophrenia, several CYP1A2 polymorphisms, three variants (*1C, and poor adherence has been directly linked to poor *1K and *11) show decreased activity.17,18 However, treatment outcomes.3 Adherence to therapy is often poor polymorphisms in CYP1A2 did not significantly influence in schizophrenia, with up to 50% of patients with schiz- the metabolism of clozapine,19 although delayed responses ophrenia being non-compliant with treatment.4,5 There- have been reported in individuals with the UM pheno- fore, optimizing compliance with therapy offers consid- type.20,21 The CYP3A4 enzyme variants are also involved erable potential to improve disease management in many in the metabolism of most antipsychotics. However, only patients. Thus, pharmacogenetic research into the factors CYP3A4*17 and *18A displayed functional variability affecting the adverse effects of antipsychotics is very with a decreased or increased activity, respectively.22 No important. connection between CYP3A5, CYP2C9 and CYP2C19 variants and the level of response or side effects to anti- Drug Metabolism-Related Genes psychotics has been reported.23-25 The world’s first phar- macogenetic microarray-based test (AmpliChip®) was Drug metabolism is a critical determinant of the thera- recently approved for clinical use.26 The AmpliChip® peutic and adverse effects of antipsychotics. There is provides comprehensive coverage of gene variations, in- strong evidence for the contribution of pharmacokinetic cluding deletions and duplications, for the CYP2D6 and factors to the clinical outcome of antipsychotic treatment. CYP2C19 genes, which play a major role in the meta- Asians have been reported to require relatively low doses bolism of an estimated 25% of all prescription drugs. of antipsychotic drugs and appear to develop toxicity at lower doses than Caucasians. These inter-ethnic variations Phase II enzymes may be attributed to pharmacokinetic differences. Genetic Phase II enzymes are responsible for the inactivation variants in Phase I and II enzymes are known to reduce of drug metabolites via conjugation reactions. N-ace- or increase their activity and subsequently to alter drug tyltransferases (NATs), thiopurine S-methyltransferases, plasma level.6-8 uridine diphosphate (UDP) glucuronosyltransferases (UGTs) and glutathione S-transferases (GSTs) are major Phase I enzymes (Cytochrome P450) enzymes involved in Phase II reactions. Some researchers Phase I oxidation is a very important metabolic process have suggested that Phase II enzyme variants may con- for antipsychotics. All antipsychotics are subject to ex- tribute to treatment variability and disease pathogenesis, tensive metabolism by various enzymes of the cytochrome especially those related to toxic environmental com- P450 (CYP) family, which play a pivotal role in the pounds.27 Genetic differences in drug metabolic alterations elimination of these drugs and therefore influence their have important implications for determination of the efficacy and toxicity. Poor metabolizers (PMs), extensive appropriate therapeutic dosage and may be related to the metabolizers (EMs) and ultrarapid metabolizers (UMs) toxic side effects of the drugs. Pharmacogenetic studies of are phenotypic presentations of individuals carrying de- pharmacokinetic factors have shown the most informative fective, normal or duplicate copies of the CYP genes, re- and clinically useful results in clinical psychiatry. Genetic spectively. CYP2D6 is the main metabolic pathway of information on the metabolic status of the individual many classical antipsychotics. The gene coding for CY- patient may be beneficial to antipsychotic treatment in P2D6 is highly variable. Out of 90 known mutations, clinical practice. It has been estimated that pretreatment four polymorphisms (*3, *4, *5 and *6) are responsible metabolic determination may decrease adverse reactions for the vast majority of inactive alleles (98%) in Cau- by 10-20% and improve drug efficacy by 10-15%.28 www.psychiatryinvestigation.org 67 Pharmacogenetics of Antipsychotics Pharmacodynamic factors been performed. Chen et al. reported that the frequency Pharmacogenetic research into pharmacodynamic fac- of the TaqI A2/A2 genotype of the DRD2 gene was tors began as a strategy for the validation of therapeutic higher in Taiwanese
Load more

Recommended publications
  • Minimum Laboratory Monitoring for Psychotropic Medications
    Minimum Laboratory Monitoring For Psychotropic Medications ANTIPSYCHOTIC MEDICATIONS GENERIC BRAND GENERIC BRAND Aripiprazole Abilify, Abilify Olanzapine Zyprexa, Zyprexa Zydis Maintena, Aristada Asenapine Saphris Paliperidone Invega, Invega Sustenna, Invega Trinza Brexpiprazole Rexulti Perphenazine Trilafon Cariprazine Vraylar Pimozide Orap Chlorpromazine Thorazine Quetiapine Seroquel, Seroquel XR Clozapine Clozaril, Fazaclo Risperidone Risperdal, Risperdal Consta, Risperdal M Tabs Fluphenazine, Fluphenazine D Prolixin, Prolixin D Thioridazine Mellaril Haloperidol, Haloperidol D Haldol, Haldol D Thiothixene Navane Iloperidone Fanapt Trifluoperazine Stelazine Loxapine Loxitane Ziprasidone Geodon Lurasidone Latuda MONITORING ANTIPSYCHOTIC FREQUENCY OF MONITORING AIMS (Abnormal Involuntary Movement Scale) On initiation of any antipsychotic medication and at least every six months thereafter, or more frequently as clinically indicated. ABDOMINAL GIRTH (>18 years old) For individuals at least 18 years old, on initiation of any medication and at least every six months thereafter, or more frequently as clinically indicated. WEIGHT & BODY MASS INDEX (BMI) On initiation of any medication and at least every six months thereafter, or more frequently as clinically indicated. HEART RATE & BLOOD PRESSSURE On initiation of any medication and at least every six months thereafter, or more frequently as clinically indicated. COMPREHENSIVE METABOLIC PANEL (CMP), On initiation of any medication affecting this parameter and at least annually LIPIDS, FASTING
    [Show full text]
  • Schizophrenia Care Guide
    August 2015 CCHCS/DHCS Care Guide: Schizophrenia SUMMARY DECISION SUPPORT PATIENT EDUCATION/SELF MANAGEMENT GOALS ALERTS Minimize frequency and severity of psychotic episodes Suicidal ideation or gestures Encourage medication adherence Abnormal movements Manage medication side effects Delusions Monitor as clinically appropriate Neuroleptic Malignant Syndrome Danger to self or others DIAGNOSTIC CRITERIA/EVALUATION (PER DSM V) 1. Rule out delirium or other medical illnesses mimicking schizophrenia (see page 5), medications or drugs of abuse causing psychosis (see page 6), other mental illness causes of psychosis, e.g., Bipolar Mania or Depression, Major Depression, PTSD, borderline personality disorder (see page 4). Ideas in patients (even odd ideas) that we disagree with can be learned and are therefore not necessarily signs of schizophrenia. Schizophrenia is a world-wide phenomenon that can occur in cultures with widely differing ideas. 2. Diagnosis is made based on the following: (Criteria A and B must be met) A. Two of the following symptoms/signs must be present over much of at least one month (unless treated), with a significant impact on social or occupational functioning, over at least a 6-month period of time: Delusions, Hallucinations, Disorganized Speech, Negative symptoms (social withdrawal, poverty of thought, etc.), severely disorganized or catatonic behavior. B. At least one of the symptoms/signs should be Delusions, Hallucinations, or Disorganized Speech. TREATMENT OPTIONS MEDICATIONS Informed consent for psychotropic
    [Show full text]
  • Amisulpride Tablets I.P. SOLIAN® THERAPEUTIC CATEGORY Anti-Psychotic COMPOSITION Solian® 50 /100 /200 /400 Each Uncoated Tablet Contains Amisulpride IP
    For the use only of a Registered Medical Practitioner (Psychiatrist) or a Hospital or a Laboratory Abridged Prescribing Information Amisulpride tablets I.P. SOLIAN® THERAPEUTIC CATEGORY Anti-psychotic COMPOSITION Solian® 50 /100 /200 /400 Each uncoated tablet contains Amisulpride IP. 50mg / 100mg / 200mg Each film coated tablet contains Amisulpride IP 400mg. THERAPEUTIC INDICATIONS Treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, and thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms. DOSAGE AND ADMINISTRATION For acute psychotic episodes, oral doses between 400 and 800 mg/d are recommended. Doses above 1200 mg/d should not be used. For patients with mixed positive and negative symptoms, doses should be adjusted to obtain optimal control of positive symptoms. Maintenance treatment should be established individually with the minimally effective dose. For patients characterised by predominant negative symptoms, oral doses between 50 mg/d and 300 mg/d are recommended. Doses should be adjusted individually. Solian® can be administered once daily at oral doses up to 300 mg, higher doses should be administered bid. The Minimum effective dose should be used. Caution in elderly. Renal & Hepatic insufficiency: Dose should be reduced. Use of amisulpride from puberty to 18 years is not recommended. SAFETY-RELATED INFORMATION Contraindications: Hypersensitivity to amisulpride or to other ingredients of the product; concomitant prolactin- dependent tumours e.g. pituitary gland prolactinomas and breast cancer; phaeochromocytoma; children up to puberty; lactation; combinations with drugs which could induce torsades de pointes and levodopa.
    [Show full text]
  • Aripiprazole Augmentation of Clomipramine Therapy In
    Dusunen Adam The Journal of Psychiatry and Neurological Sciences 2016;29:167-172 Case Report / Olgu Sunumu DOI: 10.5350/DAJPN2016290209 Aripiprazole Augmentation Filiz Izci1, Murat Yalcin2, Sumeyye Yasemin Kurtulus Calli2, of Clomipramine Therapy in Yagmur Sever3, Rabia Bilici3 1Istanbul Bilim University, Faculty of Medicine, Treatment-Resistant Department of Psychiatry, Istanbul - Turkey 2Kocaeli Derince Training and Research Hospital, Department of Psychiatry, Kocaeli - Turkey Obsessive-Compulsive 3Erenkoy Training and Research Hospital for Psychiatric and Neurological Disorders, Istanbul - Turkey Disorder: Case Series ABSTRACT Aripiprazole augmentation of clomipramine therapy in treatment-resistant obsessive-compulsive disorder: case series Obsessive-compulsive disorder (OCD) is a chronic disorder characterized by recurrent intrusive thoughts and repetitive rituals, causing significant distress and functional loss. Studies show evidence about serotonergic and dopaminergic mechanisms in neuropathogenesis of OCD. Selective serotonin re-uptake inhibitors (SSRI) are considered as first-line treatment in OCDs, but treatment resistance may occur in 40-60% of cases treated with SSRIs. Augmentation of antidepressants with atypical antipsychotics is an important treatment option in treatment-resistant patients with OCD. In this article, we aimed to present five OCD cases with treatment-resistance in which we obtained good outcomes, with addition of aripiprazole 10-30mg per day to clomipramine therapy. Address reprint requests to / Yazışma adresi:
    [Show full text]
  • Current P SYCHIATRY
    Current p SYCHIATRY N ew Investigators Tips to manage and prevent discontinuation syndromes Informed tapering can protect patients when you stop a medication Sriram Ramaswamy, MD Shruti Malik, MBBS, MHSA Vijay Dewan, MD Instructor, department of psychiatry Foreign medical graduate Assistant professor Creighton University Department of psychiatry Omaha, NE University of Nebraska Medical Center Omaha, NE bruptly stopping common psychotropics New insights on psychotropic A —particularly antidepressants, benzodi- drug safety and side effects azepines, or atypical antipsychotics—can trigger a discontinuation syndrome, with: This paper was among those entered in the 2005 • rebound or relapse of original symptoms Promising New Investigators competition sponsored • uncomfortable new physical and psycho- by the Neuroleptic Malignant Syndrome Information Service (NMSIS). The theme of this year’s competition logical symptoms was “New insights on psychotropic drug safety and • physiologic withdrawal at times. side effects.” To increase health professionals’ awareness of URRENT SYCHIATRY 1 C P is honored to publish this peer- the risk of these adverse effects, this article reviewed, evidence-based article on a clinically describes discontinuation syndromes associated important topic for practicing psychiatrists. with various psychotropics and offers strategies to NMSIS is dedicated to reducing morbidity and anticipate, recognize, and manage them. mortality of NMS by improving medical and psychiatric care of patients with heat-related disorders; providing
    [Show full text]
  • Clinical Review, Adverse Events
    Clinical Review, Adverse Events Drug: Carbamazepine NDA: 16-608, Tegretol 20-712, Carbatrol 21-710, Equetro Adverse Event: Stevens-Johnson Syndrome Reviewer: Ronald Farkas, MD, PhD Medical Reviewer, DNP, ODE I 1. Executive Summary 1.1 Background Carbamazepine (CBZ) is an anticonvulsant with FDA-approved indications in epilepsy, bipolar disorder and neuropathic pain. CBZ is associated with Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), closely related serious cutaneous adverse drug reactions that can be permanently disabling or fatal. Other anticonvulsants, including phenytoin, phenobarbital, and lamotrigine are also associated with SJS/TEN, as are members of a variety of other drug classes, including nonsteriodal anti-inflammatory drugs and sulfa drugs. The incidence of CBZ-associated SJS/TEN has been considered “extremely rare,” as noted in current U.S. drug labeling. However, recent publications and postmarketing data suggest that CBZ- associated SJS/TEN occurs at a much higher rate in some Asian populations, about 2.5 cases per 1,000 new exposures, and that most of this increased risk is in individuals carrying a specific human leukocyte antigen (HLA) allele, HLA-B*1502. This HLA-B allele is present in about 5- to 20% of many, but not all, Asian populations, and is also present in about 2- to 4% of South Asians/Indians. The allele is also present at a lower frequency, < 1%, in several other ethnic groups around the world (although likely due to distant Asian ancestry). About 10% of U.S. Asians carry HLA-B*1502. HLA-B*1502 is generally not present in the U.S.
    [Show full text]
  • Is Aristada (Aripiprazole Lauroxil) a Safe and Effective Treatment for Schizophrenia in Adult Patients? Kyle J
    Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Student Dissertations, Theses and Papers Scholarship 2017 Is Aristada (Aripiprazole Lauroxil) a Safe and Effective Treatment For Schizophrenia In Adult Patients? Kyle J. Knowles Philadelphia College of Osteopathic Medicine Follow this and additional works at: https://digitalcommons.pcom.edu/pa_systematic_reviews Part of the Psychiatry Commons Recommended Citation Knowles, Kyle J., "Is Aristada (Aripiprazole Lauroxil) a Safe and Effective Treatment For Schizophrenia In Adult Patients?" (2017). PCOM Physician Assistant Studies Student Scholarship. 381. https://digitalcommons.pcom.edu/pa_systematic_reviews/381 This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student Dissertations, Theses and Papers at DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Physician Assistant Studies Student Scholarship by an authorized administrator of DigitalCommons@PCOM. For more information, please contact [email protected]. Is Aristada (Aripiprazole Lauroxil) a Safe and Effective Treatment For Schizophrenia In Adult Patients? Kyle J. Knowles, PA-S A SELECTIVE EVIDENCE BASED MEDICINE REVIEW In Partial Fulfillment of the Requirements For The Degree of Master of Science In Health Sciences- Physician Assistant Department of Physician Assistant Studies Philadelphia College of Osteopathic Medicine Philadelphia, Pennsylvania December 16, 2016 ABSTRACT OBJECTIVE: The objective of this selective EBM review is to determine whether or not “Is Aristada (aripiprazole lauroxil) a safe and effective treatment for schizophrenia in adult patients?” STUDY DESIGN: Review of three randomized controlled studies. All three trials were conducted between 2014 and 2015. DATA SOURCES: One randomized, controlled trial and two randomized, controlled, double- blind trials found via Cochrane Library and PubMed.
    [Show full text]
  • Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice
    pharmaceuticals Article Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice Geng-Ruei Chang 1,* , Po-Hsun Hou 2,3, Wei-Cheng Yang 4, Chao-Min Wang 1 , Pei-Shan Fan 1, Huei-Jyuan Liao 1 and To-Pang Chen 5,* 1 Department of Veterinary Medicine, National Chiayi University, 580 Xinmin Road, Chiayi 60054, Taiwan; [email protected] (C.-M.W.); [email protected] (P.-S.F.); [email protected] (H.-J.L.) 2 Department of Psychiatry, Taichung Veterans General Hospital, 1650 Taiwan Boulevard (Section 4), Taichung 40705, Taiwan; [email protected] 3 Faculty of Medicine, National Yang-Ming University, 155 Linong Street (Section 2), Taipei 11221, Taiwan 4 School of Veterinary Medicine, National Taiwan University, 1 Roosevelt Road (Section 4), Taipei 10617, Taiwan; [email protected] 5 Division of Endocrinology and Metabolism, Show Chwan Memorial Hospital, 542 Chung-Shan Road (Section 1), Changhua 50008, Taiwan * Correspondence: [email protected] (G.-R.C.); [email protected] (T.-P.C.); Tel.: +886-5-2732946 (G.-R.C.); +886-4-7256166 (T.-P.C.) Abstract: Doxepin is commonly prescribed for depression and anxiety treatment. Doxepin-related disruptions to metabolism and renal/hepatic adverse effects remain unclear; thus, the underlying mechanism of action warrants further research. Here, we investigated how doxepin affects lipid Citation: Chang, G.-R.; Hou, P.-H.; change, glucose homeostasis, chromium (Cr) distribution, renal impairment, liver damage, and fatty Yang, W.-C.; Wang, C.-M.; Fan, P.-S.; liver scores in C57BL6/J mice subjected to a high-fat diet and 5 mg/kg/day doxepin treatment for Liao, H.-J.; Chen, T.-P.
    [Show full text]
  • SAFETY of the ELECTROCONVULSIVE THERAPY and AMISULPRIDE COMBINATION Rozália Takács1, Zsolt Iványi2, Gabor S
    Psychiatria Danubina, 2013; Vol. 25, No. 1, pp 76-79 Brief report © Medicinska naklada - Zagreb, Croatia SAFETY OF THE ELECTROCONVULSIVE THERAPY AND AMISULPRIDE COMBINATION Rozália Takács1, Zsolt Iványi2, Gabor S. Ungvari3, 4 & Gábor Gazdag1,5 1Department of Psychiatry and Psychotherapy, Faculty of Medicine, Semmelweis University, Budapest, Hungary 2 Department of Anesthesiology and Intensive Therapy, Faculty of Medicine, Semmelweis University, Budapest, Hungary 3University of Notre Dame, Australia 4Marian Centre, Perth, Australia 5Consultation–Liaison Psychiatric Service, Szent István and Szent László Hospitals, Budapest, Hungary received: 21.10.2011; revised: 16.1.2012; accepted: 2.12.2012 SUMMARY Background: Electroconvulsive therapy is frequently considered when pharmacotherapy is ineffective. In such cases the combination of the two treatment modalities are commonly used. Amisulpiride, a second generation antipsychotic drug is used in the treatment of schizophrenia and psychotic depression. When amisulpiride is ineffective as a monotherapy, combination with ECT could be an option to enhance its efficacy. To the best of our knowledge, to date there have been no data about the safety of this combination. Subjects and methods: Medical notes of all patients who were given ECT while on amisulpiride were selected from the archives of the Department of Psychiatry, Semmelweis University Medical School, Budapest, covering a 10-year period. A randomly selected matched control group was formed from patients who underwent ECT but were not taking amisulpiride. Patients in both groups also received a variety of psychotropic drugs other than amisulpide. Side effects were compared between the two groups of patients. Results: Twenty patients received amisulpride with ECT. The most common side effects were headache, hypertension, tachycardia, nausea, dizziness, confusion, psychomotor agitation, sialorrhea, and prolonged seizure activity.
    [Show full text]
  • Ziprasidone (Geodon®)
    Ziprasidone (Geodon®) This sheet talks about exposure to ziprasidone in pregnancy and while breastfeeding. This information should not take the place of medical care and advice from your healthcare provider. What is ziprasidone? Ziprasidone is a medication that has been used to treat bipolar disorder, schizophrenia, and schizoaffective disorder. Ziprasidone belongs to a group of medications called atypical antipsychotics or second-generation antipsychotics. A brand name is Geodon®. I take ziprasidone. Can it make it harder for me to get pregnant? A reported side effect of ziprasidone is sexual dysfunction (problems with sexual desire, sexual arousal, orgasms, or sexual pain disorders). If a person has sexual dysfunction, it might make it harder for to get pregnant. I just found out that I am pregnant. Should I stop taking ziprasidone? Talk with your healthcare providers before making any changes to how you take this medication. For some people, the benefits of staying on an antipsychotic medication during pregnancy can outweigh any potential concerns. Does taking ziprasidone increase the chance for miscarriage? Miscarriage can occur in any pregnancy. It is not known if taking ziprasidone would increase this chance for miscarriage. There are no well controlled studies on ziprasidone use during pregnancy in humans. One prescription- based study saw a slightly higher chance of a miscarriage among people who were pregnant and filled a prescription for ziprasidone in pregnancy. This type of study cannot tell us if the person actually used the medication. In addition, since untreated or uncontrolled mood disorders can increase the chance of miscarriage, it might have been the pregnant person’s condition that led to the miscarriage.
    [Show full text]
  • Paper Clip—High Risk Medications
    You belong. PAPER CLIP—HIGH RISK MEDICATIONS Description: Some medications may be risky for people over 65 years of age and there may be safer drug choices to treat some conditions. It is recommended that medications are reviewed regularly with your providers/prescriber to ensure patient safety. Condition Treated Current Medication(s)-High Risk Safer Alternatives to Consider Urinary Tract Infections (UTIs), Nitrofurantoin Bactrim (sulfamethoxazole/trimethoprim) or recurrent UTIs, or Prophylaxis (Macrobid, or Macrodantin) Trimpex/Proloprim/Primsol (trimethoprim) Allergies Hydroxyzine (Vistaril, Atarax) Xyzal (Levocetirizine) Anxiety Hydroxyzine (Vistaril, Atarax) Buspar (Buspirone), Paxil (Paroxetine), Effexor (Venlafaxine) Parkinson’s Hydroxyzine (Vistaril, Atarax) Symmetrel (Amantadine), Sinemet (Carbidopa/levodopa), Selegiline (Eldepryl) Motion Sickness Hydroxyzine (Vistaril, Atarax) Antivert (Meclizine) Nausea & Vomiting Hydroxyzine (Vistaril, Atarax) Zofran (Ondansetron) Insomnia Hydroxyzine (Vistaril, Atarax) Ramelteon (Rozerem), Doxepin (Silenor) Chronic Insomnia Eszopiclone (Lunesta) Ramelteon (Rozerem), Doxepin (Silenor) Chronic Insomnia Zolpidem (Ambien) Ramelteon (Rozerem), Doxepin (Silenor) Chronic Insomnia Zaleplon (Sonata) Ramelteon (Rozerem), Doxepin (Silenor) Muscle Relaxants Cyclobenazprine (Flexeril, Amrix) NSAIDs (Ibuprofen, naproxen) or Hydrocodone Codeine Tramadol (Ultram) Baclofen (Lioresal) Tizanidine (Zanaflex) Migraine Prophylaxis Elavil (Amitriptyline) Propranolol (Inderal), Timolol (Blocadren), Topiramate (Topamax),
    [Show full text]
  • Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss
    Supplemental Material can be found at: /content/suppl/2020/12/18/73.1.202.DC1.html 1521-0081/73/1/202–277$35.00 https://doi.org/10.1124/pharmrev.120.000056 PHARMACOLOGICAL REVIEWS Pharmacol Rev 73:202–277, January 2021 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MICHAEL NADER Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss Antonio Inserra, Danilo De Gregorio, and Gabriella Gobbi Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, Quebec, Canada Abstract ...................................................................................205 Significance Statement. ..................................................................205 I. Introduction . ..............................................................................205 A. Review Outline ........................................................................205 B. Psychiatric Disorders and the Need for Novel Pharmacotherapies .......................206 C. Psychedelic Compounds as Novel Therapeutics in Psychiatry: Overview and Comparison with Current Available Treatments . .....................................206 D. Classical or Serotonergic Psychedelics versus Nonclassical Psychedelics: Definition ......208 Downloaded from E. Dissociative Anesthetics................................................................209 F. Empathogens-Entactogens . ............................................................209
    [Show full text]